Similarly, some other studies also could not find any association of MRP2 with chemotherapy outcome, such as in breast cancer patients (n = 59) treated with either anthracyclines or hormone therapy or both16, or in ovarian carcinoma patients (n = 61)8 treated with different protocols that included platinum-containing drugs. This evidence concerns the gene ABCC2 and ovarian carcinoma.